vs
FVCBankcorp, Inc.（FVCB）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
ARS Pharmaceuticals, Inc.的季度营收约是FVCBankcorp, Inc.的1.7倍（$28.1M vs $16.9M），FVCBankcorp, Inc.同比增速更快（4377.5% vs -67.6%）
FVCBankcorp是总部位于美国弗吉尼亚州的银行控股公司，旗下运营社区银行FVCbank，面向大西洋中部地区的中小企业、专业人士及个人客户提供存款、贷款、按揭、财富管理等各类个人及商业银行金融服务。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
FVCB vs SPRY — 直观对比
营收规模更大
SPRY
是对方的1.7倍
$16.9M
营收增速更快
FVCB
高出4445.1%
-67.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.9M | $28.1M |
| 净利润 | — | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | 43.7% | -147.6% |
| 净利率 | — | -147.1% |
| 营收同比 | 4377.5% | -67.6% |
| 净利润同比 | — | -182.8% |
| 每股收益（稀释后） | $0.31 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVCBSPRY
| Q4 25 | $16.9M | $28.1M | ||
| Q3 25 | $416.0K | $32.5M | ||
| Q2 25 | $15.8M | $15.7M | ||
| Q1 25 | $382.0K | $8.0M | ||
| Q4 24 | $378.0K | $86.6M | ||
| Q3 24 | $412.0K | $2.1M | ||
| Q2 24 | $415.0K | $500.0K | ||
| Q1 24 | $359.0K | $0 |
净利润FVCBSPRY
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $5.6M | $-51.2M | ||
| Q2 25 | $5.7M | $-44.9M | ||
| Q1 25 | $5.2M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $4.7M | $-19.1M | ||
| Q2 24 | $4.2M | $-12.5M | ||
| Q1 24 | $1.3M | $-10.3M |
营业利润率FVCBSPRY
| Q4 25 | 43.7% | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | 45.9% | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% | ||
| Q1 24 | — | — |
净利率FVCBSPRY
| Q4 25 | — | -147.1% | ||
| Q3 25 | 1341.1% | -157.4% | ||
| Q2 25 | 36.0% | -285.6% | ||
| Q1 25 | 1352.1% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 1133.3% | -925.0% | ||
| Q2 24 | 1001.2% | -2503.2% | ||
| Q1 24 | 373.3% | — |
每股收益（稀释后）FVCBSPRY
| Q4 25 | $0.31 | $-0.41 | ||
| Q3 25 | $0.31 | $-0.52 | ||
| Q2 25 | $0.31 | $-0.46 | ||
| Q1 25 | $0.28 | $-0.35 | ||
| Q4 24 | $0.27 | $0.52 | ||
| Q3 24 | $0.25 | $-0.20 | ||
| Q2 24 | $0.23 | $-0.13 | ||
| Q1 24 | $0.07 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $253.6M | $114.3M |
| 总资产 | $2.3B | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资FVCBSPRY
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
总债务FVCBSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FVCBSPRY
| Q4 25 | $253.6M | $114.3M | ||
| Q3 25 | $249.8M | $147.7M | ||
| Q2 25 | $243.2M | $192.3M | ||
| Q1 25 | $242.3M | $229.0M | ||
| Q4 24 | $235.4M | $256.8M | ||
| Q3 24 | $230.8M | $201.0M | ||
| Q2 24 | $226.5M | $215.2M | ||
| Q1 24 | $220.7M | $223.9M |
总资产FVCBSPRY
| Q4 25 | $2.3B | $327.7M | ||
| Q3 25 | $2.3B | $372.8M | ||
| Q2 25 | $2.2B | $313.5M | ||
| Q1 25 | $2.2B | $327.3M | ||
| Q4 24 | $2.2B | $351.2M | ||
| Q3 24 | $2.3B | $217.6M | ||
| Q2 24 | $2.3B | $222.0M | ||
| Q1 24 | $2.2B | $227.6M |
负债/权益比FVCBSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.9M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | $23.8M | — |
| 自由现金流率自由现金流/营收 | 140.7% | — |
| 资本支出强度资本支出/营收 | 0.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.0M | — |
8季度趋势，按日历期对齐
经营现金流FVCBSPRY
| Q4 25 | $23.9M | $-43.5M | ||
| Q3 25 | $7.6M | $-47.0M | ||
| Q2 25 | $3.3M | $-39.6M | ||
| Q1 25 | $5.4M | $-40.7M | ||
| Q4 24 | $18.2M | $42.0M | ||
| Q3 24 | $4.7M | $-14.5M | ||
| Q2 24 | $1.6M | $-7.3M | ||
| Q1 24 | $7.2M | $-6.7M |
自由现金流FVCBSPRY
| Q4 25 | $23.8M | — | ||
| Q3 25 | $7.6M | $-47.2M | ||
| Q2 25 | $3.3M | $-39.6M | ||
| Q1 25 | $5.4M | $-40.8M | ||
| Q4 24 | $18.1M | $41.7M | ||
| Q3 24 | $4.6M | $-14.6M | ||
| Q2 24 | $1.5M | $-7.3M | ||
| Q1 24 | $7.1M | $-6.8M |
自由现金流率FVCBSPRY
| Q4 25 | 140.7% | — | ||
| Q3 25 | 1818.0% | -145.4% | ||
| Q2 25 | 20.8% | -252.2% | ||
| Q1 25 | 1413.6% | -512.1% | ||
| Q4 24 | 4786.0% | 48.2% | ||
| Q3 24 | 1121.8% | -706.3% | ||
| Q2 24 | 361.2% | -1463.4% | ||
| Q1 24 | 1988.3% | — |
资本支出强度FVCBSPRY
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 0.2% | 0.6% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 4.2% | 1.1% | ||
| Q4 24 | 37.3% | 0.3% | ||
| Q3 24 | 14.1% | 6.8% | ||
| Q2 24 | 12.8% | 7.6% | ||
| Q1 24 | 3.9% | — |
现金转化率FVCBSPRY
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVCB
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
